IDH1 and central nervous system cancer: In this study, we compared the early-passage cell cultures derived from patients’ glioma samples, which were different in their IDH1 R132H mutation status supplemented with dissimilar CD44 expression, to find the peculiar nanomechanical signatures characterizing different brain cancer cells.